Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial 23S ribosomal RNA (23S rRNA) is a key catalytic and structural component of the large (50S) subunit of the bacterial ribosome. It plays a fundamental role in protein synthesis by forming the peptidyl transferase center (PTC), which catalyzes peptide bond formation during translation elongation, and by shaping the nascent peptide exit tunnel (NPET) through which newly synthesized polypeptide chains leave the ribosome. Because of its essential role in bacterial viability and its structural divergence from eukaryotic cytoplasmic ribosomes, 23S rRNA is a highly successful target for several classes of clinically important antibiotics, including macrolides, lincosamides, streptogramins, oxazolidinones, and pleuromutilins. These drugs bind to specific sites on the 23S rRNA, such as the PTC or the NPET, to physically block translation or peptide bond formation, leading to bacterial cell death or growth inhibition. However, the clinical utility of these agents is increasingly threatened by resistance mechanisms, such as target site mutations (e.g., A2058G) or enzymatic methylation of the rRNA by Erm methyltransferases. Additionally, off-target binding to human mitochondrial ribosomes, which share structural homology with bacterial ribosomes, can lead to significant toxicities such as myelosuppression and lactic acidosis.
Inhibition of bacterial protein synthesis by binding to the 23S rRNA of the 50S ribosomal subunit, blocking peptidyl transferase activity or sterically obstructing the nascent peptide exit tunnel.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial 23S ribosomal RNA (23S rRNA).